JonesResearch analyst Debanjana Chatterjee initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci’s artificial intelligence-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity, the analyst tells investors in a research note. The firm says the company sets itself apart from competitors with its large scale proprietary training data, zero-shot generative AI model for de novo antibody design, and integrated high throughput in house wet lab screening and validation capacity.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABSI:
- Cathie Wood’s ARK Investment bought 400.3K shares of Absci today
- Absci management to meet virtually with KeyBanc
- Absci Corporation Advances AI-Driven Drug Development
- Absci reports Q3 EPS (24c), consensus (21c)
- Absci expects cash to fund operations into 1H27
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
